FDA warns of serious genital infection link with diabetes drug

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration (FDA) has warned that a serious genital infection has been reported in patients taking a certain class of diabetes drugs, with one death and 11 others hospitalised. Reuters Health reports that the warning pertains to a class of medicines called SGLT2 inhibitors, first approved in 2013 to lower blood sugar in adults with type 2 diabetes.

The US health regulator has also called for including this risk in the drugs’ labelling. The SGLT2 inhibitors approved by the FDA include Johnson & Johnson’s Invokana, Eli Lilly & Co’s Jardiance, as well those from Bristol-Myers Squibb, Astra Zeneca, Merck & Co and Pfizer.

The report says the companies did not immediately respond to a request for comment.

Patients are at risk of the infection known as Fournier’s gangrene, an extremely rare but life-threatening bacterial infection of the tissue under the skin that surrounds the genital area, the FDA is quoted in the report as saying.

The bacteria usually enter the body through a cut and quickly spread. Having diabetes is a risk factor for developing Fournier’s gangrene.

The FDA said it identified 12 cases of Fournier’s gangrene – 7 in men and 5 in women – between March 2013 and May 2018. One patient died, while some required multiple disfiguring surgeries and developed complications, the agency said.

The infection developed within several months of the patients starting an SGLT2 inhibitor and the drug was stopped in most cases, the FDA said.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.